AChE/BChE-IN-30

AChE/BChE-IN-30 (Compound 3g) is a Cholinesterase dual-target competitive inhibitor. AChE/BChE-IN-30 can inhibit AChE and BChE with IC50 values of 0.338 and 2.087 μM and Ki values of 0.045 and 0.789 μM. AChE/BChE-IN-30 has no obvious toxicity to human umbilical vein endothelial cells (HUVEC) and does not inhibit the CYP2C19 enzyme. AChE/BChE-IN-30 can be used for the research of neurological disease, such as Alzheimer's disease[1].

Product Specifications

UNSPSC

12352005

Target

Cholinesterase (ChE)

Related Pathways

Neuronal Signaling

Field of Research

Neurological Disease

Smiles

N#CC1=CC=C(C2=CSC(N3N=C(C4=CC=C(OC)C(OC)=C4)CC3C5=CC=C(C)S5)=N2)C=C1

Molecular Formula

C26H22N4O2S2

Molecular Weight

486.61

References & Citations

[1]Kaya B, et al. Design, Synthesis, and Molecular Docking Studies of Novel Pyrazoline-Thiazoles as Cholinesterase Dual-Target Inhibitors for the Treatment of Alzheimer's Disease. ACS Omega. 2025 Aug 22;10 (34) :38427-38439.